1. Atherosclerotic cardiovascular disease, primary or secondary prevention 2. Heterozygous familial hypercholesterolemia

Misc. Antilipemic Drugs

Distribution: Vd: 18 L. Protein binding: 99.3% to plasma proteins. Metabolism: Hepatic; primarily through metabolism of the acyl glucuronide; reversibly converted by aldo-keto reductase enzyme to an active metabolite (ESP15228), which is also converted to a glucuronide conjugate. Half-life elimination: 21 ± 11 hours. Time to peak: 3.5 hours. Excretion: Feces (30%; <5% as unchanged drug); urine (<5% as unchanged drug; ~70% of total dose as bempedoic acid and metabolites). 禁忌症：

Serious hypersensitivity reaction (eg, angioedema)

bempedoic acid should be discontinued if pregnancy occurs.

Bempedoic acid is present in human milk. Other agents may be preferred when treatment is needed in a breastfeeding patient.

Hyperuricemia, Tendon rupture, Thrombocytosis, Kidney impairment

1. Atherosclerotic cardiovascular disease, primary or secondary prevention: 180 mg once daily 2. Heterozygous familial hypercholesterolemia: 180 mg once daily. 3. Avoid coadministration of bempedoic acid with pravastatin doses greater than 40 mg. 4. Avoid coadministration of bempedoic acid with simvastatin doses greater than 40 mg.

No data are available.

No dose adjustment is necessary in patients with mild or moderate renal impairment. There are limited data available in patients with severe renal impairment.

No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or B). No data are available in patients with severe hepatic impairment (Child-Pugh C)

Store at temperatures below 30°C.